Tethys Builds A Case For Pre-Diabetes Algorithm-Based Screening

Diagnostics start-up Tethys Bioscience is laying the groundwork for its first product - a lab test it says will improve screening of the more than 50 million people at near-term risk for developing type-2 diabetes and help identify the best candidates for early-stage intervention

More from Archive

More from Medtech Insight